Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C18H34ClN2O8PS
CAS Number:
Molecular Weight:
504.96
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
clindamycin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
SMILES string
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O
InChI
1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1
InChI key
UFUVLHLTWXBHGZ-MWBQRTRKSA-N
General description
Clindamycin is a lincosamide antibiotic which is considered as a semisynthetic derivative of lincomycin. It is mainly used as an antimicrobial agent.
Application
Clindamycin phosphate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Clindamycin Phosphate Gel
- Clindamycin Phosphate Vaginal Cream
- Clindamycin Phosphate Topical Suspension
- Clindamycin Phosphate Vaginal Inserts
- Clindamycin Phosphate Topical Solution
- Clindamycin Injection
Biochem/physiol Actions
Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Antibacterial and antiprotozoal antibiotic of the licosamide class.
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Clindamycin phosphate
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
D W Scott et al.
The Canadian veterinary journal = La revue veterinaire canadienne, 39(12), 753-756 (1998-12-23)
Clindamycin hydrochloride capsules (11 mg/kg body weight, q24 h) were administered orally to 20 dogs with deep staphylococcal pyoderma. Response to therapy was excellent in 100% of the dogs. Duration of therapy varied from 21 to 91 d, with an
Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream.
M F Trexler et al.
The American journal of gastroenterology, 92(11), 2112-2113 (1997-11-15)
Vuk Uskoković et al.
Journal of pharmaceutical sciences, 103(2), 567-579 (2014-01-03)
Nanoparticulate composites of hydroxyapatite (HAp) and chitosan were synthesized by ultrasound-assisted sequential precipitation and characterized for their microstructure at the atomic scale, surface charge, drug release properties, and combined antibacterial and osteogenic response. Crystallinity of HAp nanoparticles was reduced because